Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...

Chimerix has a 52-week low of $0.75 and a 52-week high of $5.53. Insider Buying and Selling In other news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction on ...

Michael T. Andriole, President and CEO of Chimerix Inc . (NASDAQ:CMRX), recently sold 7,370 shares of the company's common stock, according to a recent SEC filing. The shares were sold at a weighted ...

Shares of Chimerix hit a new 52-week high Tuesday after the biopharmaceutical company said the Food and Drug Administration granted a priority review for its proposed dordaviprone treatment for a ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Equities research analysts at Wedbush boosted their FY2028 earnings per share estimates for shares of Chimerix in a research note issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now ...

Chimerix (CMRX) announced the FDA has accepted its New Drug Application, or NDA, seeking accelerated approval for dordaviprone as a treatment ...

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced ...

DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement ...

Chimerix ...

Investing.com -- Chimerix（纳斯达克股票代码：CMRX）股价上涨12.5%，此前该公司宣布美国食品和药物管理局（FDA）已接受其新药申请（NDA），用于治疗复发性H3 ...